Prevalence of muscle dysfunction concomitant with osteoporosis in a home-dwelling Danish population aged 65–93 years - The Copenhagen Sarcopenia Study

Nielsen, Barbara Rubek; Andersen, Hanne Elkjær; Haddock, Bryan; Hovind, Peter; Schwarz, Peter; Suetta, Charlotte

doi:10.1016/j.exger.2020.110974

Cited by 34 publications

(33 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, elderly patients have a higher risk for sarcopenia and osteoporosis [7] and are at a higher risk of experiencing side effects related to the administered drugs than non-elderly patients [8]. However, information regarding the effects of SGLT2 inhibitors on elderly patients remains inadequate.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study

et al. 2020

View full text Add to dashboard Cite

Introduction: To compare the effects of ipragliflozin, a sodium-glucose transporter 2 inhibitor, with those of metformin on visceral fat (as well as muscles and bones) in Japanese elderly patients with type 2 diabetes (T2D), we conducted a sub-analysis of a prospective, multicenter, blinded-endpoint randomizedcontrolled study. Methods: In total, 103 patients with T2D (body mass index C 22 kg/m 2 ; glycated hemoglobin, 7-10%) and being treated with sitagliptin (a dipeptidyl peptidase-4 inhibitor) were included and randomized to receive ipragliflozin or metformin. The primary outcome was the change in visceral fat area measured using computed tomography 24 weeks following treatment. The secondary outcomes included changes in subcutaneous and total fat area, muscle volume, bone density measured using computed tomography, handgrip strength, bone markers, plasma glucose, insulin, homeostasis model assessment (HOMA)2-beta, HOMA2-R, glycated hemoglobin, lipid panel, Electronic supplementary material The online version of this article (

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In a previous study of 500 women aged 60–85, compared with healthy participants, the prevalence of osteoporosis in patients with sarcopenia increased by 2.515-fold [ 44 ]. Another study found that the prevalence of osteoporosis in patients with sarcopenia increased by 7.3 times [ 45 ]. Recently, we also found that administered TWK-10 improved aged-related bone loss in aged mouse models (Lee CC et.…”

Section: Discussionmentioning

confidence: 99%

Lactobacillus plantarum TWK10 Improves Muscle Mass and Functional Performance in Frail Older Adults: A Randomized, Double-Blind Clinical Trial

Lee

Lee³

et al. 2021

Microorganisms

View full text Add to dashboard Cite

Sarcopenia is a condition in which there is a loss of muscle caused by aging and it is one of the most significant factors that affects physical fragility. In recent years, the role of the gut–muscle axis has garnered attention as, along with the gut microbiota, it potentially plays a significant role in muscle regeneration, in addition to nutritional supplements and exercise training. Past studies have found that supplementation with Lactobacillus plantarum TWK10 could effectively increase the muscle mass of animals or adult humans. Therefore, in this study, we investigated whether the supplementation of L. plantarum TWK10 produces increased muscle mass and improves the functional performance of elderly persons with mild fragility. A total of 68 elderly subjects were recruited, of which 13 subjects were excluded or withdrew from the study. We adopted a double-blind design, and the 55 subjects were randomly divided into three groups: the placebo group, the TWK10 low-dose group (2 × 1010 CFU/day) (TWK10-L), and the TWK10 high-dose group (6 × 1010 colony-forming unit (CFU)/day) (TWK10-H). For 18 weeks, all subjects were required to regularly take experimental samples, perform functional activity testing, and have their body composition analyzed before the study and every six weeks after the intervention. Finally, 17 subjects in the placebo group, 12 subjects in the TWK10-L group, and 13 subjects in the TWK10-H group finished the study. It was found that supplementation with TWK10 had a tendency to increase and improve muscle mass, left hand grip strength, lower limb muscle strength, and gait speed and balance after the sixth week, especially in the TWK10-H group, and, as the supplement time was longer up to the 18th week, it had an even greater effect (p < 0.05). In conclusion, consecutive supplementation of L. plantarum TWK10 for more than six weeks could effectively improve the muscle strength and endurance of the elderly, reducing sarcopenia and physical fragility. This trial was registered at clinicaltrials.gov as NCT04893746.

show abstract

“…BMD values were significantly lower in sarcopenic older women, and sarcopenic adults had a fourfold higher risk of having co-existing osteoporosis compared with non-sarcopenic adults in a Belgian study [35]. Lastly, studies have shown that being diagnosed with sarcopenia was associated with a high risk of having osteoporosis and vice versa [20][21][22][36][37][38].…”

Section: Prevalence Of Osteosarcopeniamentioning

confidence: 92%

“…Estimates vary considerably, between 5 and 37% depending on the population and definition of sarcopenia used. The highest rates were observed in those with fractures [21,31]. In a study of 316 community-dwelling Chinese adults aged 65 years and over, 10.4% of men and 15.1% of women were found to be osteosarcopenic [33].…”

Section: Prevalence Of Osteosarcopeniamentioning

confidence: 99%

“…A positive relationship between muscle and bone mass decline over a year was recognized in older individuals in the SarcoPhAge study [20], whereas an increase in the risk of fracture and a decline in muscle strength were associated with a decrease in spine and hip BMD [20]. In the Copenhagen Sarcopenia Study, BMD was lower among individuals with sarcopenia [21] and a large study of women in Japan showed that the relative skeletal muscle index was positively correlated with BMD of the lumbar spine and total hip [22]. Finally, in a cross-sectional study of premenopausal, perimenopausal and postmenopausal women, a linear decline in both muscle mass and bone density was noted, showing significant changes in postmenopausal compared to premenopausal women [23].…”

Section: Coexistence Of Poor Bone and Muscle Measurementsmentioning

confidence: 99%

See 1 more Smart Citation

A pas de deux of osteoporosis and sarcopenia: osteosarcopenia

et al. 2021

View full text Add to dashboard Cite

The musculoskeletal conditions osteoporosis and sarcopenia are highly prevalent in older adults. Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone, whereas sarcopenia is identified by the loss of muscle strength, function and mass. Osteoporosis represents a major health problem contributing to millions of fractures worldwide on an annual basis, whereas sarcopenia is associated with a range of adverse physical and metabolic outcomes. They both affect physical and social function, confidence and quality of life as well as contributing to high health-care costs worldwide. Osteosarcopenia is the term given when both conditions occur concomitantly and it has been suggested that interactions between these two conditions may accelerate individual disease progression as co-existence of osteoporosis and sarcopenia is associated with higher morbidity from falls, fracture, disability as well as mortality. In this review, we will outline the epidemiology, pathogenesis and clinical consequences of osteosarcopenia and discuss available management strategies.

show abstract

Prevalence of muscle dysfunction concomitant with osteoporosis in a home-dwelling Danish population aged 65–93 years - The Copenhagen Sarcopenia Study

Cited by 34 publications

References 44 publications

Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study

Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study

Lactobacillus plantarum TWK10 Improves Muscle Mass and Functional Performance in Frail Older Adults: A Randomized, Double-Blind Clinical Trial

A pas de deux of osteoporosis and sarcopenia: osteosarcopenia

Contact Info

Product

Resources

About